Molecular and Cellular Biochemistry

, Volume 341, Issue 1–2, pp 139–148 | Cite as

VEGF and IL-4 gene variability and its association with the risk of coronary heart disease in north Indian population

  • R. C. Sobti
  • Nishi Maithil
  • Hitender Thakur
  • Yashpaul Sharma
  • K. K. Talwar
Article

Abstract

Vascular endothelial growth factor (VEGF) is a potent angiogenic growth factor that has been shown to play a significant role in neovascularization during inflammation in atherosclerotic plaques, formation of collateral vessels to an area of ischemic myocardium and neovascularization at the edges of a myocardial infarction during its repair. Interleukin-4 (IL-4) has important role in immune cell chemotaxis, formation of endothelial cell adhesion molecules and has numerous anti-inflammatory effects which prevent the complications of atherosclerosis, the primary cause of coronary heart disease (CHD). In this study, we have analyzed the effect of 1154 A/G polymorphism of VEGF and 70 bp VNTR polymorphism of intron 3 in IL-4 genes in coronary heart disease (CHD) patients (n = 300) and their age matched controls (n = 300). To analyze polymorphic alleles, ARMS-PCR and RFLP techniques were used. Multiple logistic regression analysis was carried out with statistical software. GG genotype was associated with a decreased risk of development of CHD (OR 0.22, 95% CI 0.12–0.38, P < 0.001). However, A allele showed an increased risk whereas G allele decreased the risk of CHD with diabetes mellitus, hypertension, chronic mental stress and positive familial history of myocardial infarction (MI)/CHD. GG genotype was found to have protective effect with alcohol intake (OR 0.34, 95% CI 0.14–0.82, P < 0.01) and central obesity (OR 0.15, 95% CI 0.04–0.56, P < 0.001). GG genotype of VEGF has also shown significant association with IL-4 (P2P2 and P1P2) genotypes.

Keywords

VEGF IL-4 Genetic polymorphism CHD Atherosclerosis Cytokine 

Notes

Acknowledgements

This work was supported by a grant from Council of Scientific and Industrial Research, Ministry of Human Resource and Development, New Delhi, India. We thank Dr. Gurbir Singh and Dr. G. S. Kalra, Fortis Hospital, Mohali, India for their kind help and co-operation.

References

  1. 1.
    Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143CrossRefPubMedGoogle Scholar
  2. 2.
    Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y (2000) Association of a T29-C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101:2783–2787PubMedGoogle Scholar
  3. 3.
    Clauss M, Gerlach M, Gerlach H, Brett J, Wamg F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D (1990) Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535–1545CrossRefPubMedGoogle Scholar
  4. 4.
    Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:3336–3343PubMedGoogle Scholar
  5. 5.
    Grosskrutz CL, Anand-Apte B, Duplaa C, Quinn TP, Terman BI, Zetter B, D’Amore PA (1999) Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res 58:128–136CrossRefGoogle Scholar
  6. 6.
    Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD (2001) Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Med 7:425–429CrossRefPubMedGoogle Scholar
  7. 7.
    Lengstrom KB, Krebs R, Nykanen AI, Tikkanen JM, Sihvola RK, Aaltola EM, Hayry PJ, Wood PJ, Alitalo K, Yla-Herttuala S, Koskinen PK (2002) Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 105:2524–2530CrossRefGoogle Scholar
  8. 8.
    Zhao Q, Egashira K, Inoue S, Usui M, Kitamoto S, Ni W, Ishibashi M, Hiasa Ki K, Ichiki T, Shibuya M, Takeshita A (2002) Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 105:1110–1115CrossRefPubMedGoogle Scholar
  9. 9.
    Asahara T, Bauters C, Kearney M, Pastore C, Bunting S, Rossow S, Ferrara N (1995) Local delivery of vascular endothelial growth factor accelerates re-endothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 91:2793–2801PubMedGoogle Scholar
  10. 10.
    Van Belle E, Maillard L, Tio FO, Isner JM (1997) Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation. Biochem Biophys Res Comm 235:311–316CrossRefPubMedGoogle Scholar
  11. 11.
    Tsurumi Y, Krasinski K, Chen D, Witzenbichler B, Kearney M, Couffinhal T, Isner JM (1997) Reciprocal relationship between VEGF and NO in the regulation of endothelial integrity. Nature Med 3:879–886CrossRefPubMedGoogle Scholar
  12. 12.
    Vincenti V, Cassano C, Rocchi M, Persico G (1996) Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93:1493–1495PubMedGoogle Scholar
  13. 13.
    Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232–1235CrossRefPubMedGoogle Scholar
  14. 14.
    Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV (2002) Polymorphisms in vascular endothelial growth factor gene are associated with increased risk of acute rejection in renal transplant recipients. J Am Soc Nephrol 13:260–264PubMedGoogle Scholar
  15. 15.
    Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV (1999) Novel polymorphisms in the promoter and 59 untranslated regions of the human vascular endothelial growth factor gene. Hum Immunol 60:1245–1249CrossRefPubMedGoogle Scholar
  16. 16.
    Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S (2002) A common polymorphism in the 59 untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635–1639CrossRefPubMedGoogle Scholar
  17. 17.
    Liao JK (2004) Statins: potent vascular anti-inflammatory agents. Int J Clin Pract 143:41–48CrossRefGoogle Scholar
  18. 18.
    Aukrust P, Yndestad A, Waehre T, Gullestad L, Halvorsen B, Damas JK (2005) Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Rev Cardiovasc Ther 3:1111–1124CrossRefPubMedGoogle Scholar
  19. 19.
    Lefer AM, Ma XL, Weyrich AS, Scalia R (1993) Mechanism of the cardioprotective effect of transforming growth factor beta 1 in feline myocardial ischemia and reperfusion. Proc Natl Acad Sci USA 90:1018–1022CrossRefPubMedGoogle Scholar
  20. 20.
    Negoro K, Kinouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J, Shimosegawa T, Toyota T (1999) Crohn’s disease is flanking region of the associated with novel polymorphisms in the tumor necrosis factor gene. Gastroenterology 117:1062–1068CrossRefPubMedGoogle Scholar
  21. 21.
    Elkarim RA, Mustafa M, Kivisakk P, Link H, Bakhiet M (1998) Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. Eur J Clin Investig 28:295–299CrossRefGoogle Scholar
  22. 22.
    Kim HM, Shin HY, Jeong HJ, Kim NS, Chae HJ, Kim HR, Song HJ, Kim KY, Baek SH, Cho KS, Moon BS, Lee YM (2000) Reduced IL-2 but elevated IL-4, IL-6, and IgE serum levels in patients with cerebral infarction during the acute stage. J Mol Neurosci 14:191–196CrossRefPubMedGoogle Scholar
  23. 23.
    Nanavaty U, Goldstein AD, Levine SJ (2001) Polymorphisms in candidate asthma genes. Am J Med Sci 321:11–16CrossRefPubMedGoogle Scholar
  24. 24.
    Bijlsma FJ, Van K, Van H, Jonge E, Tilanus N, Gmelig-Meyling FH, de Weger RA (2002) Acute cardiac transplant rejection is associated with low frequencies of interleukin-4 producing helper T-lymphocytes rather than with interleukin-4 promoter or splice variants. Hum Immunol 63:317–323CrossRefPubMedGoogle Scholar
  25. 25.
    Maksymowych WP, Suarez-Almazor ME, Buenviaje H, Cooper BL, Degeus C, Thompson M, Russell AS (2002) HLA and cytokine gene polymorphisms in relation to occurrence of palindromic rheumatism and its progression to rheumatoid arthritis. J Rheumatol 29:2319–2326PubMedGoogle Scholar
  26. 26.
    Nakayama EE, Meyer L, Iwamoto A, Persoz A, Nagai Y, Rouzioux C, Delfraissy JF, Debre P, McIlroy D, Theodorou I, Shioda T (2003) SEROCO Study Group Protective effect of interleukin-4589T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load. J Infect Dis 185:1183–1186CrossRefGoogle Scholar
  27. 27.
    Bugawan TL, Mirel DB, Valdes AM, Panelo A, Pozzilli P, Erlich HA (2003) Association and interaction of the IL4R, IL4, and IL13 loci with type 1 diabetes among Filipinos. Am J Hum Genet 72:1505–1514CrossRefPubMedGoogle Scholar
  28. 28.
    Zee RYL, Cook NR, Cheng S, Reynolds R, Erlich HA, Lindpaintner K, Ridker PM (2004) Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet 13:389–396CrossRefPubMedGoogle Scholar
  29. 29.
    Debora SF, Flynt L, Bourgeois K, Panettieri RA, Stephanie A (2006) Interleukin-13 and interleukin-4 induce vascular endothelial growth factor release from airway smooth muscle cells role of vascular endothelial growth factor genotype. Am J Respir Cell Mol Biol 34:213–218CrossRefGoogle Scholar
  30. 30.
    Tsai FJ, Chang CH, Chen CC, Hsia TC, Chen HY, Chen WC (2005) Interleukin-4 gene intron-3 polymorphism is associated with transitional cell carcinoma of the urinary bladder. BJU Int 95:430–435CrossRefGoogle Scholar
  31. 31.
    Field JK, Liloglou T, Xinarianos S, Prime GP, Fielding W, Walshaw JM, Turnbull L (1999) Genetic alterations in bronchial lavage as a potential marker for individuals with a high risk of developing lung cancer. Cancer Res 59:2690–2695PubMedGoogle Scholar
  32. 32.
    Howell WM, Ali S, Rose-Zerilli MJ, Ye S (2005) VEGF polymorphisms and severity of atherosclerosis. J Med Genet 42:485–490CrossRefPubMedGoogle Scholar
  33. 33.
    Mout R, Willemze R, Landegent JE (1991) Repeat polymorphisms in the interleukin-4 gene. Nucl Acids Res 19:3763CrossRefPubMedGoogle Scholar
  34. 34.
    Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812–816PubMedGoogle Scholar
  35. 35.
    Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian K, Folkman J (2003) Inhibition of plaque neovascularization reduces marcrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 100:4736–4741CrossRefPubMedGoogle Scholar
  36. 36.
    Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P (2004) Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 53:861–864CrossRefPubMedGoogle Scholar
  37. 37.
    Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106:468–471CrossRefPubMedGoogle Scholar
  38. 38.
    Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 4:167–173CrossRefGoogle Scholar
  39. 39.
    Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8:R22CrossRefPubMedGoogle Scholar
  40. 40.
    Mccarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Feles RA, Howell WM (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 12:3369–3372Google Scholar
  41. 41.
    Del Bo R, Scarlato M, Ghezzi S, Maestreni A, Sjolind L, Forsblom C, Wessman M, Groop PH, Comi GP, Bresolin M, Luzi L, Zerbini G (2006) VEGF gene variability and type 1 diabetes: evidence for a protective role. Immunogenetics 58:107–112CrossRefPubMedGoogle Scholar
  42. 42.
    Yang B, Cross DF, Ollerenshaw M, Millward BA, Demaine AG (2003) Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complic 17:1–6CrossRefGoogle Scholar
  43. 43.
    Buracznska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L (2007) Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetic patients. Nephrol Dial Transpl 22:827–832CrossRefGoogle Scholar
  44. 44.
    Tedgui A, Mallat Z (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86:515–581CrossRefPubMedGoogle Scholar
  45. 45.
    Chang YH, Huang CN, Wu CY, Shiau MY (2005) Association of interleukin-10 A-592C and T-819C polymorphisms with type 2 diabetes mellitus. Hum Immunol 66:1258–1263CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • R. C. Sobti
    • 1
  • Nishi Maithil
    • 1
  • Hitender Thakur
    • 1
  • Yashpaul Sharma
    • 2
  • K. K. Talwar
    • 2
  1. 1.Department of BiotechnologyPanjab UniversityChandigarhIndia
  2. 2.Department of CardiologyPost Graduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations